SCHEMBL7477944

SCHEMBL7477944

CC(C)(C)OC(=O)Nc1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.66
RAB9A P51151 5/20 0.66
GAA P10253 2/20 0.66
SLC6A2 P23975 1/20 0.56
SLC6A3 Q01959 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
LMNA P02545 1/20 0.56
MAPT P10636 5/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
MEN1 O00255 3/20 0.52
KDM4E B2RXH2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NAMPT P43490 3/20 0.52
SYK P43405 1/20 0.52
POLB P06746 1/20 0.50
THRB P10828 1/20 0.50
ELANE P08246 1/20 0.49
TPSAB1 Q15661 1/20 0.49
TPSD1 Q9BZJ3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1252896 0.95 KMT2A (0.59) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL2409894 0.90 RAB9A (0.59) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL7043026 0.89 POLB (0.62) KMT2ARAB9AGAAMAPTALDH1A1
SCHEMBL8650559 0.88 RAB9A (0.56) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL7425443 0.86 RAB9A (0.71) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL25732533 0.86 JAK2 (0.60) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL24848155 0.84 KMT2A (0.69) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL29129126 0.83 KDM1A (0.54) KMT2ARAB9AGAAMAPTMEN1
SCHEMBL6288470 0.83 SYK (0.57) KMT2ARAB9AGAASLC6A2SLC6A3
SCHEMBL29142984 0.83 L3MBTL1 (0.59) KMT2ARAB9AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2022-04-12 US disclosed
CN-111356456-A 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor 夏威夷大学 2020-06-30 CN disclosed
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 WO disclosed
US-20130136691-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2013-05-30 US disclosed
US-8444954-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-05-21 US disclosed
US-8420050-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-04-16 US disclosed
US-20120009122-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2012-01-12 US disclosed
US-20110250133-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2011-10-13 US disclosed
US-7922998-B2 bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy BRACCO IMAGING S.P.A. (IT) 2011-04-12 US disclosed
US-20110052491-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2011-03-03 US disclosed
US-7850947-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2010-12-14 US disclosed
US-7611692-B2 bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy BRACCO IMAGING S.P.A. (IT) 2009-11-03 US disclosed
US-20090175786-A1 Gastrin Releasing Peptide Compounds BRACCO IMAGING S.P.A. (IT) 2009-07-09 US disclosed
US-20080008649-A1 Gastrin Releasing Peptide Compounds BRACCO IMAGING S.P.A. (IT) 2008-01-10 US disclosed
EP-1183235-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2002-03-06 EP disclosed
WO-2000071510-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2000-11-30 WO disclosed
US-5786379-A Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors STAT3, JAK2, STAT5A KMT2A 510/4885RAB9A 2697/4885GAA 1716/4885
US-20130136691-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, GHRHR KMT2A 4582/4885RAB9A 542/4885GAA 396/4885
US-20090175786-A1 Gastrin Releasing Peptide Compounds GRPR, SSTR5, GIPR KMT2A 2078/4885RAB9A 1754/4885GAA 1821/4885
US-20080008649-A1 Gastrin Releasing Peptide Compounds GRPR, SSTR5, GIPR KMT2A 2078/4885RAB9A 1754/4885GAA 1821/4885
US-20120009122-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, CCKBR KMT2A 2523/4885RAB9A 2016/4885GAA 1172/4885
US-20110250133-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, GHRHR KMT2A 4582/4885RAB9A 542/4885GAA 396/4885
US-20110052491-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, CCKBR KMT2A 4200/4885RAB9A 1091/4885GAA 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.